HeXun Biosciences Co., Ltd.
HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.
HeXun Biosciences Co., Ltd. (6986) - Total Liabilities
Latest total liabilities as of September 2025: NT$89.01 Million TWD
Based on the latest financial reports, HeXun Biosciences Co., Ltd. (6986) has total liabilities worth NT$89.01 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HeXun Biosciences Co., Ltd. - Total Liabilities Trend (2020–2024)
This chart illustrates how HeXun Biosciences Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
HeXun Biosciences Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of HeXun Biosciences Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Metal Sky Star Acquisition Corporation Ordinary shares
NASDAQ:MSSA
|
USA | $7.85 Million |
|
Q32 Bio Inc
NASDAQ:QTTB
|
USA | $76.23 Million |
|
Healthcare Integrated Technologies Inc
PINK:HITC
|
USA | $849.40K |
|
Articore Group Ltd
AU:ATG
|
Australia | AU$63.56 Million |
|
Metacon AB
ST:META
|
Sweden | Skr103.40 Million |
|
THINKWARE Corporation
KQ:084730
|
Korea | ₩164.72 Billion |
|
Chien Shing Stainless Steel Co Ltd
TW:2025
|
Taiwan | NT$642.47 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down HeXun Biosciences Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HeXun Biosciences Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HeXun Biosciences Co., Ltd. (2020–2024)
The table below shows the annual total liabilities of HeXun Biosciences Co., Ltd. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$86.34 Million | -11.96% |
| 2023-12-31 | NT$98.07 Million | +9.84% |
| 2022-12-31 | NT$89.28 Million | +11.79% |
| 2021-12-31 | NT$79.86 Million | -7.67% |
| 2020-12-31 | NT$86.50 Million | -- |